References

  1. Efavirenz. Full Prescribing Information, Dosage & Side Effects. Available at www.mims.com/USA/drug/info/efavirenz/. Accessed 12 February 2012

  2. Adkins JC, Noble S. Efavirenz. Drugs. 1998;56(6):1055-64; 1065-6. This article on PubMed

  3. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002; 22:930-933. This article on PubMed

  4. Bahal SM, Romansky JM, Alvarez FJ. Medium chain triglycerides as vehicle for palatable oral liquids. Pharm Dev Technol. 2003;8(1):111-5. This article on PubMed

  5. Sathigari S, Chadha G, Lee YH, Wright N, et al. Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. AAPS PharmSciTech. 2009;10(1):81-7. This article on PubMed

  6. Curi AL, Freeman G, Kapembwa M, Pavesio C. Retinal toxicity due to Efavirenz. Eye (Lond). 2001 Apr;15(Pt 2):246-8. This article on PubMed

  7. Pasticci MB, Bonora S, DI Candilo F, Lapalorcia LM, Palladino N, Baldelli F. Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis. J Chemother. 2007;19(1):110. This article on PubMed

  8. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15:71-75. This article on PubMed

  9. Boscacci, Rémy Ta; Buclin, Thierryb; Furrer, Hansjakoba; et al. A case of voluntary intoxication with efavirenz and lamivudine. AIDS. 2006 ;20 (9): 1352-1354. This article on PubMed

  10. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229-37. This article on PubMed